| Authors | Burnham, SC. Bourgeat, Pierrick Doré, Vincent Savage, G. Brown, B. Laws, S. Maruff, P. Salvado, O. Ames, D. Martins, RN. Masters, CL. Rowe, CC. Villemagne, VL. |
|---|---|
| Type | Journal Article (Original Research) |
| Journal | The Lancet Neurology |
| Year of Publication | 2016 |
| URL | http://www.thelancet.com/journals/laneur/article/PIIS1474-4422(16)30125-9/abstract |
| DOI | http://dx.doi.org/10.1016/S1474-4422(16)30125-9 |
| Abstract | SummaryBackground Brain amyloid β (Aβ) deposition and neurodegeneration have been documented in about 50-60% of cognitively healthy elderly individuals (aged 60 years or older). The long-term cognitive consequences of the presence of Alzheimer's disease pathology and neurodegeneration, and whether they have an independent or synergistic effect on cognition, are unclear. We aimed to characterise the long-term clinical and cognitive trajectories of healthy elderly individuals using a two-marker (Alzheimer's disease pathology and neurodegeneration) imaging construct. Methods Between Nov 3, 2006, and Nov 25, 2014, 573 cognitively healthy individuals in Melbourne and Perth, Australia, (mean age 73·1 years [SD 6·2]; 58% women) were enrolled in the Australian Imaging, Biomarker and Lifestyle (AIBL) study. Alzheimer's disease pathology (A) was determined by measuring Aβ deposition by PET, and neurodegeneration (N) was established by measuring hippocampal volume using MRI. Individuals were categorised as A−N−, A+N−, A+N+, or suspected non-Alzheimer's disease pathophysiology (A−N+, SNAP). Clinical progression, hippocampal volume, standard neuropsychological tests, and domain-specific and global cognitive composite scores were assessed over 6 years of follow-up. Linear mixed effect models and a Cox proportional hazards model of survival were used to evaluate, compare, and contrast the clinical, cognitive, and volumetric trajectories of patients in the four AN categories. Findings 50 (9%) healthy individuals were classified as A+N+, 87 (15%) as A+N−, 310 (54%) as A−N−, and 126 (22%) as SNAP. APOE ε4 was more frequent in participants in the A+N+ (27; 54%) and A+N− (42; 48%) groups than in the A−N− (66; 21%) and SNAP groups (23; 18%). The A+N− and A+N+ groups had significantly faster cognitive decline than the A−N− group (0·08 SD per year for AIBL-Preclinical AD Cognitive Composite [PACC]; p<0·0001; and 0·25; p<0·0001; respectively). The A +N+ group also had faster hippocampal atrophy than the A−N− group (0·04 cm3 per year; p=0·02). The SNAP group generally did not show significant decline over time compared with the A−N− group (0·03 SD per year [p=0·19] for AIBL-PACC and a 0·02 cm3 per year increase [p=0·16] for hippocampal volume), although SNAP was sometimes associated with lower baseline cognitive scores (0·20 SD less than A−N− for AIBL-PACC). Within the follow-up, 24% (n=12) of individuals in the A+N+ group and 16% (n=14) in the A+N− group progressed to amnestic mild cognitive impairment or Alzheimer's disease, compared with 9% (n=11) in the SNAP group. Interpretation Brain amyloidosis, a surrogate marker of Alzheimer's disease pathology, is a risk factor for cognitive decline and for progression from preclinical stages to symptomatic stages of the disease, with neurodegeneration acting as a compounding factor. However, neurodegeneration alone does not confer a significantly different risk of cognitive decline from that in the group with neither brain amyloidosis or neurodegeneration. Funding CSIRO Flagship Collaboration Fund and the Science and Industry Endowment Fund (SIEF), National Health and Medical Research Council, the Dementia Collaborative Research Centres programme, McCusker Alzheimer's Research Foundation, and Operational Infrastructure Support from the Government of Victoria. |
http://www.ibas.org.au/what-we-do/publications/3872845
SHIFT WORK AND BREASTFEEDING PROJECT
Researchers at Austin Health are looking for volunteers to participate in a study exploring the impact shift work has on breast milk composition. Participants will be compensated with a $100 gift voucher.
Interstitial lung disease (ILD) is a chronic lung condition that causes stiff lungs and restricts sufferers from taking a deep breath. Exercise in a gym, or swimming, walking or riding a bike, can help...
Sleep apnea is a condition where breathing is abnormal during sleep. There are two main forms of sleep apnea: obstructive and central. For obstructive sleep apnea, breathing is reduced because the airway...
A/PROF MARK HOWARD AWARDED MAJOR COMPETITIVE MRFF GRANT
IBAS leads project to revolutionize Home Ventilation with $1.2 million grant for Assoc. Prof Mark Howard's research titled "Synchronise non-invasive ventilation at home".
PROF ANNE HOLLAND RECEIVES PRESTIGIOUS RESEARCH AWARD
Prof Anne Holland receives prestigious award for Excellent in Research Engagement and Impact from Monash University.
WORLD SLEEP DAY ON 17TH MARCH 2023
The benefits of quality sleep and to acknowledge the issue of sleep problems and their medical, educational, and social aspects as well as the prevention and management of sleep disorders, is promoted on World Sleep Day on the 17th March 2023.
A/PROF MARK HOWARD IS LISTED IN 'THE AUSTRALIAN'
The Australian's Research magazine names the top researcher and top research institution in each field of research, based on the number of citations for papers published in the top 20 journals in each field over the past five years.
© 2024 Institute for Breathing and Sleep. All Rights Reserved. ABN 39 093 685 879
Powered by Helmut Design | Manage
